<DOC>
	<DOCNO>NCT00845663</DOCNO>
	<brief_summary>To compare bioavailability single 400 mg dose certolizumab pegol solution ( 2 x 200mg subcutaneous injection ) inject either pre-filled syringe ( reference ) auto-injection device ( test ) .</brief_summary>
	<brief_title>Comparison Bioequivalence Study : Pre-filled Syringe ( Reference ) Versus Auto-injection Device ( Test )</brief_title>
	<detailed_description />
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Age : 1855 year . A Body mass Index ( BMI ) 18 28 kg/m Good physical mental health status determine basis medical history general clinical examination Electrocardiogram clinical laboratory test interpret `` normal '' QuantiFERONTB test negative female subject : medically accept method contraception prohibit concomitant medication administer vaccine immunoglobulin month precede certolizumab pegol injection history significant disease , allergies history drug and/or alcohol abuse hepatic enzyme induce drug within 2 month study drug administration drug influence immune response antibiotic month precede inclusion know intolerant PEG previously receive certolizumab pegol previously receive antibody product within 5half life antibody within 3 month start study history tuberculosis serum hepatitis carrier Hepatitis B surface antigen ( HBs Ag ) , Hepatitis C antibody HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>Comparison Bioequivalence Study</keyword>
</DOC>